|
WO2010005532A1
|
|
Tumor-initiating cells and methods of use
|
|
WO2009052211A1
|
|
Compositions and methods for enhancing lymphangiogenesis
|
|
US2010150841A1
|
|
Use of Tumor Necrosis Factor-Alpha P75 Receptor for the Reduction of Inflammation
|
|
WO2008085221A2
|
|
Therapeutic use of cd31 expressing cells
|
|
WO2008057313A2
|
|
Methods of using e2f2 for the treatment of hypertension
|
|
WO2008066630A2
|
|
Methods for reprogramming adult somatic cells and uses thereof
|
|
US2009105148A1
|
|
Compositions and methods for treating myocardial infarction
|
|
WO2007050648A2
|
|
Use of tumor necrosis factor- receptor p75 for treatment of ischemia-induced neovascularization
|
|
WO2007047950A2
|
|
Use of sumoylation inhibitors for the treatment of neurodegenerative disease
|
|
WO2007047963A2
|
|
Use of bone-marrow derived stem cells to treat ischemia
|
|
US2009325911A1
|
|
Use of Androgens for the Treatment of Parkinson's Disease
|
|
WO2007047882A2
|
|
Combination of cxcr4 antagonist and morphogen to increase angiogenesis
|
|
WO2007142651A1
|
|
Methods and compositions for the treatment of neuropathy
|
|
WO2006122090A2
|
|
Screening assays for compounds regulating dj-i expression
|
|
US2010028312A1
|
|
Stably transformed bone marrow-derived cells and uses thereof
|
|
WO2006104749A2
|
|
Compositions and methods for detecting compounds that treat a neurological disorder
|
|
WO2006047198A2
|
|
Composition and method for using a cytokine to treat restenosis
|
|
US7122007B2
|
|
Methods of and systems and devices for assessing intracranial pressure non-invasively
|
